Lung cancer maintains a high morbidity and mortality rate globally despite significant
advancements in detection and therapy in the era of precision medicine. Excisional biopsy …

Simple Summary Lung cancer remains a leading cause of cancer-related mortality globally,
requiring new diagnostic and therapeutic approaches. This research arises from the need to …

Background Liquid biopsy provides a non-invasive approach that enables detecting
circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) using blood specimens …

Purpose Genomic profiling is a major component for first-line treatment decisions in patients
with non-small cell lung cancer (NSCLC) and the timeliness of biomarker testing is essential …

Introduction The treatment approach for recently diagnosed advanced non-small cell lung
cancer (NSCLC) with EGFR mutations primarily relies on confirming the tissue diagnosis as …

The advent of molecular profiling and the generalization of next generation sequencing in
oncology has enabled the identification of patients who could benefit from targeted agents …

The completion of multiple national pediatric precision oncology platform trials and the
incorporation of standardized molecular profiling into the diagnostic care of pediatric and …

Simple Summary A liquid biopsy (LB) is now considered to be a valuable diagnostic tool for
advanced and metastatic nonsquamous nonsmall cell lung cancer (NS-NSCLC) patients …

Simple Summary Circulating tumor DNA (ctDNA) is a non-invasive method of identifying and
monitoring genitourinary cancers, including prostate, bladder, and renal cell carcinoma, via …

Solid tumour tissue has traditionally been used for cancer molecular diagnostics. Recently,
biomarker assessment in blood or liquid biopsies has become relevant because it allows …